Filing Flows › Supernus Pharmaceuticals (SUPN) › R&D spending
Supernus Pharmaceuticals (SUPN) R&D spending by quarter
Supernus Pharmaceuticals' R&D spending was $25.8M in Q3 2026 (third quarter 2026), -13% from Q2 2026. Over the last 7 quarters it ranged from $22.1M (Q2 2025) to $39.4M (Q1 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $25.8M | -13% | -12% |
| Q2 2026 | $29.5M | -25% | +33% |
| Q1 2026 | $39.4M | +42% | +46% |
| Q4 2025 | $27.8M | -5% | — |
| Q3 2025 | $29.4M | +33% | — |
| Q2 2025 | $22.1M | -18% | — |
| Q1 2025 | $26.9M | — | — |
Q3 2026 at a glance
Supernus Pharmaceuticals, Q3 2026: revenue $227M (+18% year over year), operating margin 9.3%, net earnings $20.9M, operating cash flow $6.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is Supernus Pharmaceuticals' R&D spending?
Supernus Pharmaceuticals' R&D spending was $25.8M in Q3 2026 (third quarter 2026), -13% from Q2 2026.
How has Supernus Pharmaceuticals' R&D spending changed?
Over the last 7 quarters it ranged from $22.1M (Q2 2025) to $39.4M (Q1 2026).
Q3 2026 results → · How Supernus Pharmaceuticals makes money →